Pure Global
NCT06214910

ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa

University of Washington·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Tuberculosis
Drug/Device/Intervention
TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Washington
Location
Sweetwaters, South Africa
Timeline & enrollment
Phase
Phase 4
Start date
Feb 20, 2024
End date
Dec 31, 2026
Enrollment
525 participants
Primary outcome

Completion of a course of TB preventive therapy (TPT)

Summary

This study will compare community-delivered, multi-month dispensing of tuberculosis
 preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of
 South African adults who are recommended to receive TB preventive therapy.
 
 We hypothesize that persons receiving multi-month dispensing of TPT in the community will
 have a higher rate of TPT completion at 3 months than persons receiving TPT via standard of
 care with monthly clinic-based refills.

ICD-10 classifications
TuberculosisLatent tuberculosisTuberculosis of other organsCongenital tuberculosisSequelae of tuberculosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06214910
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06214910 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Washington and is currently Recruiting. The study focuses on Tuberculosis. Target enrollment is 525 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.